醫學系

Medicine & Life Sciences

1. Taiwan 100%
2. Neoplasms 30%
3. Population 28%
4. Cohort Studies 26%
5. Stroke 26%
6. Apoptosis 25%
7. Therapeutics 23%
8. Meta-Analysis 22%
9. Confidence Intervals 20%
10. Proteins 17%
11. Wounds and Injuries 15%
12. Hepatocellular Carcinoma 14%
13. Arsenic 14%
14. Odds Ratio 14%
15. Mortality 14%
16. In Vitro Techniques 14%
17. Systematic Reviews 14%
18. Lung 14%
19. Genes 13%
20. Neoplasm Metastasis 13%
21. Randomized Controlled Trials 13%
22. Serum 13%
23. Breast Neoplasms 13%
24. Kidney 12%
25. Lipopolysaccharides 12%
26. Colorectal Neoplasms 12%
27. Inflammation 12%
28. Databases 12%
29. Chronic Renal Insufficiency 12%
30. Autophagy 11%
31. Reactive Oxygen Species 11%
32. Down-Regulation 11%
33. Incidence 11%
34. Phosphorylation 11%
35. Endothelial Cells 10%
36. Growth 10%
37. National Health Programs 10%
38. Pharmaceutical Preparations 10%
39. Macrophages 10%
40. Blood Platelets 10%
41. Nitric Oxide 9%
42. Survival 9%
43. Brain 9%
44. Gene Expression 9%
45. Liver 9%
46. Carcinoma 8%
47. Metabolic Syndrome 8%
48. Retrospective Studies 8%
49. Traumatic Brain Injury 8%
50. Oxidative Stress 8%
51. Up-Regulation 8%
52. MicroRNAs 8%
53. Atrial Fibrillation 8%
54. Antioxidants 8%
55. Prostatic Neoplasms 8%
56. Biomarkers 8%
57. Renal Dialysis 8%
58. Lung Neoplasms 8%
59. Heme Oxygenase-1 8%
60. Cell Proliferation 8%
61. Cardiac Myocytes 8%
62. Glucose 8%
63. Child 8%
64. Elderly 8%
65. Cytokines 8%
66. Nanoparticles 8%
67. Recurrence 7%
68. Messenger RNA 7%
69. Hypertension 7%
70. Blood Pressure 7%
71. Bipolar Disorder 7%
72. Glioblastoma 7%
73. Calcium 7%
74. Pain 7%
75. Bone and Bones 7%
76. Cell Movement 7%
77. Drug Therapy 7%
78. Schizophrenia 7%
79. Skin 7%
80. Colonic Neoplasms 7%
81. Case-Control Studies 7%
82. Pulmonary Veins 7%
83. Magnetic Resonance Imaging 7%
84. Infections 7%
85. Tuberculosis 7%
86. Cell Line 7%
87. Cell Death 7%
88. Control Groups 7%
89. Exercise 6%
90. Parkinson Disease 6%
91. Logistic Models 6%
92. Glioma 6%
93. ErbB Receptors 6%
94. Nitric Oxide Synthase Type II 6%
95. Extracellular Signal-Regulated MAP Kinases 6%
96. Fibrosis 6%
97. Methylation 6%
98. Non-Small Cell Lung Carcinoma 6%
99. Peroxisome Proliferator-Activated Receptors 6%
100. Sepsis 6%